Auris Medical
Cochlear therapies

Innovative Treatments for Inner Ear Disorders

4th Quarter 2018 Financial Results & Business Update

March 14, 2019

NASDAQ: EARS

Forward-looking Statements

This presentation and the accompanying oral commentary may contain statements may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” or the negative of these terms and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, Auris Medical’s need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical’s product candidates and that such trials will not meet its endpoints , the clinical utility of Auris Medical’s product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical’s intellectual property position and Auris Medical’s financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical’s capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Auris Medical’s Annual Report on Form 20-F for the year ended December 31, 2017 and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Fourth Quarter 2018 Highlights

Auris Medical
Cochlear therapies

Intranasal Betahistine Program

- Phase 1 trial confirmed superior bioavailability with intranasal betahistine as well as good safety and tolerability
- Intranasal betahistine program progressing towards proof-of-concept studies in acute vertigo (AM-125) and antipsychotic-induced weight gain (AM-201)

Other Development Programs

- Detailed results from HEALOS Phase 3 trial with Sonsuvi® published in peer-reviewed journal
- Defined development pathway for Keyzilen®

Operational & Financial

- Full repayment of loan facility to result in a significant reduction of interest expense and strengthened balance sheet
- Redomiciliation to Bermuda to reduce costs and better align with U.S. capital market practices



Program Updates

Auris Medical
Cochlear therapies

AM-125: Progressing Towards Trial Initiation



Dillon NP et al. (2017), Otol Neurotol. 38(3): 441-7.

- Multicenter randomized controlled Phase 2 trial to evaluate AM-125 in the **t**reatment of **a**cute peripheral **ver**tigo following vestibular **s**chwannoma resection (TRAVERS)
- 138 patients
- Clinical trial site selection in several European countries and Canada
- Primary efficacy outcomes: time standing on foam, tandem Romberg test
- Anticipated milestones:
  - First site initiation in Q1 2019
  - Ramp-up during Q2 2019
  - Interim analysis in Fall 2019

Design of TRAVERS Phase 2 Trial

Part A
N = 50 + 16

- Patients with acute vertigo following vestibular schwannoma resection
- Dose Escalation: 5 steps with AM-125 vs. placebo (t.i.d.)
- Open-label oral betahistine (48 mg)

Interim Analysis

- Determine dose response curve
- Pick two doses for Part B
- Re-assess sample size and powering assumptions for Part B

Part B
N = [72]

- Assess AM-125 high dose and low dose against placebo

AM-201: Proof-of-Concept Trial Initiation



- Phase 1b proof-of-concept trial with AM-201 in antipsychotic-induced weight gain
- Single European trial site
- 50 healthy volunteers
- Efficacy outcomes:
  - Primary – reduction in weight gain
  - Secondary – reduction in somnolence
- All approvals received
- Anticipated milestones:
  - Recruitment to start in Q1 2019
  - Read-out in Summer 2019

Design of AM-201 Phase 1b Trial

Auris Medical
Cochlear therapies

Screening

- Healthy male or female volunteers 18-50 years of age
- BMI 18-25 kg/m^2
- Dose escalation: 5 steps with AM-201 vs. placebo (t.i.d.)

Titration OLZ

- Titrate OLZ up to 10 mg (7.5 mg) q.d. within first week
- Subjects who do not tolerate OLZ or who gain clinically relevant amount of weight or high glucose level to be replaced

Maintenance

- Maintain OLZ dose for three weeks

Other Betahistine Developments

- Acquired Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi Syndrome (PWS).

- Entered into a binding Letter of Intent to acquire exclusive rights to in-license two U.S. patents relating to the use of betahistine for the treatment of atypical depression and attention-deficit / hyperactivity disorder (ADHD).

- Announced peer-reviewed article shows that betahistine promotes the retrieval of forgotten memories in mice and human beings.

Sonsuvi® / AM-111 Update



Original Study

OPEN

Efficacy and Safety of AM-111 in the Treatment of Acute Unilateral Sudden Deafness—A Double-blind, Randomized, Placebo-controlled Phase 3 Study

*Hinrich Staecker, †Galina Jokovic, ‡Sergey Karpishchenko, §Andrea Kienle-Gogolok, ||Andrzej Krzyzaniak, ¶Chia-Der Lin, #Pavel Navratil, **Ventzislav Tzvetkov, ††Nida Wright, and ‡‡Thomas Meyer

- Detailed results from HEALOS Phase 3 trial published in *Otology & Neurotology* shows promising results of AM-111 in subpopulation of patients with profound hearing loss

- Structured partnering process initiated
  - Supported by international transaction advisory firm targeting potential partners for AM-111 development program
  - Discussions with potentially interested parties ongoing

Keyzilen® / AM-101 Update

Auris Medical
Cochlear therapies

Keyzilen
esketamine hydrochloride

- Continued work on our later-stage Keyzilen / AM-101 program in acute inner ear tinnitus with defined development path forward
- In-depth analyses of outcomes from TACTT2 and TACTT3 and related AMPACT1 and AMPACT2 trials provide good understanding of issues with elements of design and conduct
- Currently exploring options for implementation through partnering and / or non-dilutive funding



Financial Update

Auris Medical
Cochlear therapies

4th Quarter and Full Year 2018 Financial Update

Auris Medical
Cochlear therapies

Select data from profit and loss account (CHF 1,000)

	3 months ended Dec 31		12 months ended Dec 31	
	2018	2017	2018	2017
Research and development	35	4,285	6,690	19,211
General and administrative	635	1,153	4,265	5,150
Operating loss	670	5,438	10,954	24,361
Net loss	3,691	4,586	11,496	24,409
Net loss per share (CHF)	0.12	1.05	0.72	5.58
Average weighted number of shares outstanding	*30,427,094*	*4,374,187*	*15,900,865*	*4,374,187*

4th Quarter and Full Year 2018 Financial Update

Auris Medical
Cochlear therapies

Select data from balance sheet (CHF 1,000)

	12 months ended Dec 31	
	2018	2017
Cash and cash equivalents	5,393	14,973
Total assets	9,877	17,826
Loan facility	1,435	10,126
Shareholders' equity	3,650	-2,162

Early Repayment of Loan Facility

- Loan facility with Hercules Capital, Inc. repaid on January 31, 2019
  - last amortization rate
  - end of term charge
- 12 months ahead of original schedule
- All covenants and collaterals in favor of Hercules lifted
- Repayment will result in
  - ✓significant reduction of interest expense (CHF 1.1 million in 2018)
  - ✓improved balance sheet
  - ✓enhanced financial flexibility

Relocating Company Domicile to Bermuda

- Transfer of the Auris Medical Holding AG from Zug, Switzerland to Hamilton, Bermuda
- Approved by extraordinary general meeting of shareholders On March 8, 2019, with an overwhelming majority
  - Also: related memorandum of continuance, and
  - New by-laws under Bermuda law
- Redomiciliation expected to become effective before end of March 2019
- Principal rationale = gain more corporate flexibility, achieve cost savings and operate under a jurisdiction that is more familiar to U.S. investors
- Update of various registration statements required

Nasdaq Listing Requirements

- Notification of failure to comply with Nasdaq $1.00 minimum bid price listing requirement (Rule 5550(a)(2)).
- Hearing before Nasdaq Hearings Panel requested where Company is to provide a plan to regain compliance
- Hearing request stayed the suspension of the Company's securities pending the determination of the Panel
- Company's common continue to trade on The Nasdaq Capital Market under the trading symbol "EARS"



Summary and Conclusion

Auris Medical
Cochlear therapies

Upcoming Value-Creating Milestones





Take care of your ears!

Auris Medical Holding AG
Bahnhofstrasse 21
CH-6300 Zug
Tel. +41 41 729 71 94 | Fax +41 61 201 13 51
www.aurismedical.com | NASDAQ: EARS

Auris Medical
Cochlear therapies